All AbMole products are for research use only, cannot be used for human consumption.
Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targeting TIGIT with an intact Fc region.TIGIT is a novel inhibitory immune checkpoint expressed primarily on the surface of T-cells and natural killer (NK) cells, which suppresses an organism's immune response to cancer. It can be used in studies related to solid tumors.
| CAS Number | 1918185-84-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[2] No authors listed. Cancer Discov. Tiragolumab Results Cast Shadow on TIGIT Pipeline
[3] Peter Sidaway. Nat Rev Clin Oncol. Tiragolumab active in PD-L1+ NSCLC
| Related TIGIT Products |
|---|
| Domvanalimab
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
